Identifying genetic variants associated with side effects of antidepressant treatment: A systematic review

IF 5.3 2区医学 Q1 CLINICAL NEUROLOGY

Progress in Neuro-Psychopharmacology & Biological Psychiatry Pub Date : 2024-10-05 DOI:10.1016/j.pnpbp.2024.111154

Gabriel da Rocha Zurchimitten , Laísa Camerini , Geison Souza Izídio , Gabriele Ghisleni

{"title":"Identifying genetic variants associated with side effects of antidepressant treatment: A systematic review","authors":"Gabriel da Rocha Zurchimitten , Laísa Camerini , Geison Souza Izídio , Gabriele Ghisleni","doi":"10.1016/j.pnpbp.2024.111154","DOIUrl":null,"url":null,"abstract":"<div><div>Major Depressive Disorder (MDD) is one of the most prevalent neurobiological disorders globally. Antidepressant medications are the first-line treatment for managing symptoms. However, over time, pharmacotherapy has been linked to several challenges, primarily due to the wide array of side effects that often reduce patient adherence to treatment. The literature suggests that these side effects may be influenced by polymorphisms in genes related to the pharmacokinetics and pharmacodynamics of antidepressants. Thus, this systematic review aimed to identify studies that investigated the association between genetic variants and side effects resulting from antidepressant treatment in individuals with MDD. Original articles indexed in the electronic databases Cochrane Library, EMBASE, MEDLINE via PubMed, and Scopus were identified. A total of 55 studies were included in the review, and data regarding the outcomes of interest were extracted. Due to the exploratory nature of the review, a narrative/descriptive synthesis of the results was performed. The risk of bias was evaluated using the Joanna Briggs Institute's tools, tailored to the design of each study. Polymorphisms in 35 genes were statistically associated with the development of side effects. A subsequent Protein-Protein Interaction Network analysis helped elucidate the key biological pathways involved in antidepressant side effects, with a view toward exploring the potential application of pharmacogenetic markers in clinical practice.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111154"},"PeriodicalIF":5.3000,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0278584624002227","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Major Depressive Disorder (MDD) is one of the most prevalent neurobiological disorders globally. Antidepressant medications are the first-line treatment for managing symptoms. However, over time, pharmacotherapy has been linked to several challenges, primarily due to the wide array of side effects that often reduce patient adherence to treatment. The literature suggests that these side effects may be influenced by polymorphisms in genes related to the pharmacokinetics and pharmacodynamics of antidepressants. Thus, this systematic review aimed to identify studies that investigated the association between genetic variants and side effects resulting from antidepressant treatment in individuals with MDD. Original articles indexed in the electronic databases Cochrane Library, EMBASE, MEDLINE via PubMed, and Scopus were identified. A total of 55 studies were included in the review, and data regarding the outcomes of interest were extracted. Due to the exploratory nature of the review, a narrative/descriptive synthesis of the results was performed. The risk of bias was evaluated using the Joanna Briggs Institute's tools, tailored to the design of each study. Polymorphisms in 35 genes were statistically associated with the development of side effects. A subsequent Protein-Protein Interaction Network analysis helped elucidate the key biological pathways involved in antidepressant side effects, with a view toward exploring the potential application of pharmacogenetic markers in clinical practice.

查看原文本刊更多论文

确定与抗抑郁治疗副作用相关的基因变异：系统综述。

重度抑郁症（MDD）是全球最普遍的神经生物学疾病之一。抗抑郁药物是控制症状的一线治疗方法。然而，随着时间的推移，药物治疗也面临着一些挑战，主要是由于药物的各种副作用往往会降低患者对治疗的依从性。文献表明，这些副作用可能受到与抗抑郁药物的药代动力学和药效学相关的基因多态性的影响。因此，本系统综述旨在确定调查 MDD 患者的基因变异与抗抑郁治疗副作用之间关系的研究。研究人员在 Cochrane Library、EMBASE、MEDLINE via PubMed 和 Scopus 等电子数据库中检索到了原创文章。共有 55 项研究被纳入综述，并提取了相关结果的数据。由于综述具有探索性，因此对结果进行了叙述/描述性综合。采用乔安娜-布里格斯研究所（Joanna Briggs Institute）的工具对偏倚风险进行了评估，并根据每项研究的设计进行了调整。据统计，35 个基因的多态性与副作用的发生有关。随后进行的蛋白质-蛋白质相互作用网络分析有助于阐明抗抑郁药物副作用所涉及的关键生物通路，从而探索药物遗传标记在临床实践中的潜在应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Progress in Neuro-Psychopharmacology & Biological Psychiatry 医学-精神病学

CiteScore

12.00

自引率

1.80%

发文量

153

审稿时长

56 days

期刊介绍： Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Issues of the journal are regularly devoted wholly in or in part to a topical subject. Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated.